When administered intraperitoneally, the combination of paclitaxel and brassinin diminished tumor growth by the downregulation of phospho-STAT3, CD31, and Ki-67 in a xenograft lung cancer model [257]. The gene discussed is PECAM1; the disease is lung cancer.